Mon panier

RON

RON Informations sur la molécule

Nom anglaisMacrophage-stimulating protein receptorNombre de médicaments commercialisés1
Nombre de médicaments cliniques2Alias de la cibleRon tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
Phase de R&D la plus avancéeApproved
Nom anglaisMacrophage-stimulating protein receptor
Alias de la cibleRon tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques2
Phase de R&D la plus avancéeApproved

RON Liste de produits

  • Attribut

    Protein (1)

  • Bibliothèque de produits

    En ligne (1)

  • Espèces

    Human (1)

  • Étiquette

    His Tag (1)

  • Marqueur

    Unconjugated (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
Human
HEK293
Human RON / MSPR Protein, His Tag (MALS verified)
Ajouter au panier
Quantité totale1
  • 1

RONContexte de la molécule

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

RONAlias de la molécule

CD136 antigen,CD136,CDw136c-met-related tyrosine kinase,EC 2.7.10,EC 2.7.10.1,macrophage stimulating 1 receptor (c-met-related tyrosine kinase),MSP R,MSP receptor,MSPR,MST1R,p185-Ron,Protein-tyrosine kinase 8,PTK8 protein tyrosine kinase 8,PTK8,Ron,RONmac

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Ningetinib TosylateCT-053-PTSA; CT-053Phase 2 ClinicalHec Pharm Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms
Details
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And CompanyBiliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
CrizotinibPF-1066; PF-2341066; PF-02341066; PF-002341066ApprovedPfizer Inc赛可瑞, XalkoriUnited StatesCarcinoma, Non-Small-Cell LungPf Prism Cv2011-08-26Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques